Medtronic is experiencing a 1.94% increase in stock price to $102.96, despite a projected 4.32% decline in earnings per share to $1.33. Analysts remain optimistic, with Wells Fargo resuming coverage at an Overweight rating and a $114 price target. The company's plans to spin out its diabetes segment and enhance its partnership with Mindray for patient monitoring technologies are also seen as positive developments amid operational risks.
“Medtronic (MDT) · was up · $102.96 · +1.94%”
“Medtronic (MDT) · had gained · 5.14% · in the past month”
“Medtronic · will report an EPS of · $1.33 · marking a 4.32% fall compared to the same quarter of the previous year”
“Medtronic · intends to spin out · diabetes segment · true”
“Wells Fargo · resumed coverage of · Medtronic · Overweight rating and $114 price target”
“Medtronic · extended its partnership with · Mindray · to integrate Microstream capnography and Nellcor pulse oximetry into Mindray’s patient monitoring platforms”
“Medtronic · is working to embed · monitoring technologies · in the ambulatory surgery center market”
“Medtronic · has · a long dividend track record · rather than rapid expansion”
“Medtronic · is currently facing · operational and balance sheet risk · that deserves closer attention from investors”
“Medtronic (MDT) · was up · $102.96 · +1.94%”
“shares of Medtronic · had gained · 5.14% · in the past month”
“Medtronic earnings report · is set to go public on · February 17, 2026”
